Maze Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Maze Therapeutics announced positive topline Phase 2 clinical data for MZE829 in kidney disease, alongside a significant net loss for 2025 and a new $200 million loan facility.
NASDAQ
Maze Therapeutics reports a year of strategic shifts, marked by significant licensing agreements and progress in its clinical programs targeting renal and cardiovascular diseases.